Aspect's platform technology constitutes an entirely new way of 3D bioprinting, engineered specifically with the capacity to fabricate physiologically complex living tissue on demand for broad applications in the life sciences. We have developed a sophisticated Lab-on-a-printer™ technology that enables unprecedented control over biomaterial composition and structure during tissue fabrication.
As a consequence, we are able to develop advanced 3D tissue models much faster and using a wide spectrum of different cells, biomaterials, and growth factors than our competition. This enables the rapid printing of macro-scale 3D structures that incorporate intricate micro-level details to generate architecturally and functionally accurate human tissues. By enabling the user to program the structure, material composition and printing process in software, Aspect has enabled the production of a massive variety of potential living structures.
Aspect Biosystems currently offers contract testing services on our 3DAirwayALI™ human tissue model. Endpoints available include barrier function, quantified protein expression by IHC or ELISA, and differentiation status (mucous hyperplasia, ciliagenesis). Our customers include pharmaceutical firms and academics who are using our services to define novel pathways in respiratory diseases.